Diversa awarded US grant for anthrax test:
This article was originally published in Clinica
Executive Summary
Diversa has received funds to develop an antibody-based test for anthrax infection. The $3.7m grant, from the US National Institute of Allergy and Infectious Diseases (NIAD), will also cover the development of therapeutic antibodies. The San Diego, California firm will use its proteomics technology and human antibody platform to screen for highly selective antibodies to new anthrax targets. Currently, anthrax testing is done through either time-consuming microbial culture or the newer PCR tests, which have been controversial.